VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has named Raju Willener as its new chief financial officer, effective immediately. The announcement, made on September 8, 2026, underscores the company's commitment to strengthening its financial and strategic operations as it advances its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener brings more than three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. In his new role, he will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, identify strategic opportunities, and contribute to the continued development of its therapeutic programs.
Before joining VERAXA, Willener served as director of corporate development at Exentis Group AG and was appointed CFO in 2025. At Exentis, he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
The appointment comes at a critical time for VERAXA, which is focused on advancing its pipeline of bispecific T cell engagers, bispecific antibody-drug conjugates (ADCs), and other innovative antibody formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and operates with a quality-by-design approach to drug development.
According to the company, Willener's expertise in capital markets and corporate development will be instrumental in navigating the financial complexities of biotech innovation. His background in managing large investment portfolios and leading M&A activities is expected to aid VERAXA in securing funding and forging strategic partnerships to accelerate its research and development efforts.
The full press release is available at https://nnw.fm/jcHOU. For more information about VERAXA Biotech and its latest updates, visit the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this announcement involve risks and uncertainties, including those detailed in the company's filings with the SEC. Investors are advised not to place undue reliance on these statements, as actual results may differ materially.
